Riccardo Perfetti - 21 Mar 2022 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Role
Chief Medical Officer
Signature
/s/ Shoshana Shendelman as attorney-in-fact
Issuer symbol
APLT
Transactions as of
21 Mar 2022
Net transactions value
+$125,797
Form type
4
Filing time
23 Mar 2022, 21:00:58 UTC
Previous filing
11 Jan 2022
Next filing
15 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLT Common Stock Purchase $23,214 +12,548 +13% $1.85 108,948 21 Mar 2022 Direct F1, F2
transaction APLT Common Stock Purchase $43,483 +21,961 +20% $1.98 130,909 22 Mar 2022 Direct F1, F3
transaction APLT Common Stock Purchase $59,100 +30,000 +23% $1.97 160,909 23 Mar 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were purchased by Dr. Perfetti in multiple transactions.
F2 Weighted average price. These shares were purchased by Dr. Perfetti in multiple transactions at prices ranging from $1.8100 to $1.9200 inclusive. The reporting undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 Weighted average price. These shares were purchased by Dr. Perfetti in multiple transactions at prices ranging from $1.9000 to $2.0900 inclusive. The reporting undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 Weighted average price. These shares were purchased by Dr. Perfetti in multiple transactions at prices ranging from $1.8600 to $2.1000 inclusive. The reporting undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.